Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
about
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsSatraplatin: leading the new generation of oral platinum agentsPhase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancerSatraplatin: an orally available platinum analog for the treatment of cancer.Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.Satraplatin in the treatment of hormone-refractory metastatic prostate cancerNew-generation platinum agents for solid tumors.Satraplatin for the therapy of castration-resistant prostate cancer.Clinical and pharmacokinetic evaluation of satraplatin.Advances in oral delivery of anti-cancer prodrugs.The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
P2860
Q26851177-81445E6C-88F4-4F8D-9089-496AAA6F0AE0Q28066801-C12C7304-4FB1-4F35-9BAA-5A9B94C97C84Q28972468-4D9D77AD-C22E-4C8B-AA99-D71F43C74EA6Q35118358-E15CB946-6D75-4445-A32A-AF4F1BF1B61FQ35945262-8A07BF1E-245B-4BD8-9EBA-79A879FD4866Q36417757-C5E5CD6D-8D0C-488B-AF55-A74FBB9401D3Q36428631-BFA6BE0F-334C-4547-AD9A-E26D6702A5ADQ36532071-D8981D7B-65D5-46EB-9099-613C205E5019Q36640945-A3D87A09-D14D-4697-AFCC-76FF234412A4Q37160386-4565E8BE-D5CF-4F48-B4AE-F1F194FBA09DQ37401326-8AA710C6-1AE3-4D23-BBA7-C80F292A2B3FQ37605845-7A2D4FDB-68DA-4A1C-8220-CA04BF10AED2Q37958009-9904CF52-FB86-42DE-AA4B-8C7822C903BDQ38862820-733546D8-5716-4651-9FE8-E9C0FF7DB656Q49123833-9CBAFEE1-D950-4BD8-8948-E31E62D9AF71
P2860
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Phase I and pharmacokinetic st ...... days in patients with cancer.
@ast
Phase I and pharmacokinetic st ...... days in patients with cancer.
@en
type
label
Phase I and pharmacokinetic st ...... days in patients with cancer.
@ast
Phase I and pharmacokinetic st ...... days in patients with cancer.
@en
prefLabel
Phase I and pharmacokinetic st ...... days in patients with cancer.
@ast
Phase I and pharmacokinetic st ...... days in patients with cancer.
@en
P2093
P1476
Phase I and pharmacokinetic st ...... days in patients with cancer.
@en
P2093
I R Judson
K R Harrap
L R Kelland
M J McKeage
P Santabárabara
P304
P356
10.1200/JCO.1997.15.7.2691
P407
P50
P577
1997-07-01T00:00:00Z